Lytix Biopharma AS

Research Lytix Biopharma AS (LYTIX) on Bullrun: market cap NOK 738.24M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerLYTIX
• ExchangeOL
• CountryNorway
• SectorHealthcare
• IndustryBiotechnology
• CurrencyNOK
• Market capNOK 738.24M
• Financial periodQ4 2025
• Net income-NOK 18.66M
• Free cash flow-NOK 19.27M

Valuation Snapshot

latest market cap is NOK 738.24M.

About Lytix Biopharma AS

Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is ruxotemitide, an oncolytic molecule that is developed for intratumoral injections, which is in Phase III clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma; and NeoLIPA Phase II study in combination with pembrolizumab.

Frequently asked questions

What is Lytix Biopharma AS's market cap?

Lytix Biopharma AS's market capitalization is NOK 738.24M.

What does Lytix Biopharma AS do?

Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States.